Key Takeaways:
A securities class action has been filed against Erasca Inc., alleging the company misled investors about its lead oncology drug ERAS-0015's preclinical data comparisons, wiping out more than half the company's market value over two trading days.
"The complaint alleges that Erasca's preclinical data for ERAS-0015 was based on improper comparisons to Revolution Medicines Inc.'s proprietary compound RMC-6236, exposing the company to patent infringement and trade secret misappropriation claims," James (Josh) Wilson, securities litigation partner at Faruqi & Faruqi LLP, said.
Erasca's stock fell 53.9% across two trading sessions beginning April 27, 2026, after the company disclosed two material events in rapid succession. Before the market opened that day, Erasca filed a Form 8-K revealing it had received a letter from RevMed's legal counsel alleging that ERAS-0015 infringes U.S. Patent No. 12,409,225 and that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures." Shares dropped $2.34, or 10.9%, from $21.49 to $19.15.
After the close on April 27, Erasca filed a separate Form 8-K reporting preliminary Phase 1 clinical data for ERAS-0015. The filing disclosed that one patient receiving 24 mg of ERAS-0015 died approximately one month after starting treatment, classified as a "Grade 3 TRAE of pneumonitis" that "progressed to Grade 5 after withdrawal of supportive care per patient decision." The company also acknowledged that comparisons between ERAS-0015 and other product candidates, including RMC-6236, were "not based on any head-to-head clinical trials" and are "inherently limited and such data may not be directly comparable." Shares fell an additional $9.25, or more than 45%, to close at $9.90 on April 28.
The class period covers investors who purchased Erasca securities between January 14, 2025 and April 26, 2026. The lead plaintiff deadline is August 10, 2026. The lawsuit alleges that Erasca and its executives violated federal securities laws by touting ERAS-0015 as a potential "best-in-class" therapy with purportedly superior preclinical results while failing to disclose that those comparisons lacked a reasonable basis and placed the company at risk of patent and trade secret disputes.
ERAS-0015 is a RAS inhibitor being developed for oncology indications. The company had positioned the drug as a potential competitor to RevMed's RMC-6236, which targets the same pathway. The allegations center on whether Erasca's preclinical comparisons to RevMed's compound were scientifically valid or constituted improper use of proprietary data.
The lawsuit's outcome could determine whether Erasca faces significant legal liability and settlement costs on top of the reputational damage from the data disclosures. Investors will watch for any further regulatory or legal developments, including potential FDA scrutiny of the Phase 1 safety signal and the company's next clinical update.
This article is for informational purposes only and does not constitute investment advice.
